Withdrawal of semaglutide results in weight regain, increased alcohol intake and metabolic disorders in a diet-induced obese hamster model of MetALD
Non-Invasive Biomarkers of Metabolic Liver DiseasE NIMBLE: Stage 2.0 - Research Design
Semaglutide 2.4 mg Weight Outcomes Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease in a Real-World Setting
Sociodemographic and Clinical Characteristics of Patients with MASH Initiating Resmitirom
US healthcare professionals’ management of metabolic dysfunction-associated steatohepatitis and knowledge of glucagon, GLP-1, and GIP receptor agonists and dual agonists
Improvements in non-invasive biomarkers and biopsy responses with the GCGR/GLP-1R dual agonist survodutide: Concordance analysis from a phase 2 trial in people with MASH and fibrosis
Real-World Semaglutide Treatment Patterns Among Patients with MASH in England: An Analysis of Primary Care Prescription Data
Survodutide improved liver histology in people with MASH and moderate-to-severe fibrosis regardless of age, sex, ethnicity, or type 2 diabetes: Subgroup analysis of a randomized phase 2 trial
Impact of Resmetirom on Liver Transplant Demand and Outcomes in MASH Patients in Germany: A Microsimulation Approach
Oral Cholate Challenge Test Characterizes Functional Differences between Child-Pugh A5 and A6
Introducing MASHtrack, an FNIH Biomarkers Consortium & NIDDK NASH CRN collaboration to validate prognostic biomarkers in MASLD and MASH
Durability of resmetirom response in patients with MASLD with up to two years of treatment in MAESTRO-NAFLD-OLE
Analysis of baseline PRO-C3 and ELF components in patients with MASH/MASLD and MASH cirrhosis and correlations between change in PRO-C3 and ELF in resmetirom-treated patients from the MAESTRO-NASH trial
Effect of Pemvidutide on Hepatic Injury, Inflammation, and Fibrosis in MASH: A Responder Analysis of the Phase 2b IMPACT Trial
Pemvidutide Treatment Yields Significant Reductions in Non-Invasive Tests of Liver Fibrosis and AI-Based Digital Pathology: Results from the Pemvidutide Phase 2b IMPACT Trial
NON-INVASIVE TESTING TO RULE-IN MODERATE TO SEVERE FIBROSIS WHILE RULING OUT CIRRHOSIS FOR THERAPEUTIC INTERVENTION IN METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS
Redesigning MASLD Monitoring: A Game-Theoretic Model for Personalized Follow-Up
Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial
Velacur as a tool to identify patients with potentially treatable disease at point-of-care
Noninvasive initiation and monitoring of the therapy with TNR-beta agonist Resmetirom (RT) using LIVERFASt, FIB-4 and Vibration-controlled transient elastography (VCTE, Fibroscan) in patients with MASH.
Two-Year Time Course of Biomarker and Imaging Responses in Well-Compensated MASH Cirrhosis Patients Treated with Resmetirom
Comparative Modulation of Adiponectin Across Select Therapeutics in Clinical Development for MASH with Fibrosis Identifies Lanifibranor as a Differentiated Metabolic Modulator.
All Copyright © Reserved by MASH-TAG
Internet Explorer is not supported by this site.
Please consider using Google Chrome or Microsoft Edge instead.
